Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis

doi:10.3390/vaccines10050771

	Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis
	Mosharaf, Md Parvez 1,2; Reza, Md Selim 1,3; Gov, Esra 4; Mahumud, Rashidul Alam 5; Mollah, Md Nurul Haque 1
	2022-05-01
发表期刊	VACCINES
卷号	10 期号:5 页码:20
摘要	Non-small-cell lung cancer (NSCLC) is considered as one of the malignant cancers that causes premature death. The present study aimed to identify a few potential novel genes highlighting their functions, pathways, and regulators for diagnosis, prognosis, and therapies of NSCLC by using the integrated bioinformatics approaches. At first, we picked out 1943 DEGs between NSCLC and control samples by using the statistical LIMMA approach. Then we selected 11 DEGs (CDK1, EGFR, F Upsilon N, UBC, M Upsilon C, CCNB1, FOS, RHOB, CDC6, CDC20, and CHEK1) as the hub-DEGs (potential key genes) by the protein-protein interaction network analysis of DEGs. The DEGs and hub-DEGs regulatory network analysis commonly revealed four transcription factors (FOXC1, GATA2, Upsilon Upsilon 1, and NFIC) and five miRNAs (miR-335-5p, miR-26b-5p, miR-92a-3p, miR-155-5p, and miR-16-5p) as the key transcriptional and post-transcriptional regulators of DEGs as well as hub-DEGs. We also disclosed the pathogenetic processes of NSCLC by investigating the biological processes, molecular function, cellular components, and KEGG pathways of DEGs. The multivariate survival probability curves based on the expression of hub-DEGs in the SurvExpress web-tool and database showed the significant differences between the low- and high-risk groups, which indicates strong prognostic power of hub-DEGs. Then, we explored top-ranked 5-hub-DEGs-guided repurposable drugs based on the Connectivity Map (CMap) database. Out of the selected drugs, we validated six FDA-approved launched drugs (Dinaciclib, Afatinib, Icotinib, Bosutinib, Dasatinib, and TWS-119) by molecular docking interaction analysis with the respective target proteins for the treatment against NSCLC. The detected therapeutic targets and repurposable drugs require further attention by experimental studies to establish them as potential biomarkers for precision medicine in NSCLC treatment.
关键词	non-small cell lung cancer gene expression profiles molecular signatures therapeutic targets and agents integrated bioinformatics approaches
DOI	10.3390/vaccines10050771
收录类别	SCI
语种	英语
WOS研究方向	Immunology ; Research & Experimental Medicine
WOS类目	Immunology ; Medicine, Research & Experimental
WOS记录号	WOS:000803470300001
出版者	MDPI
引用统计	被引频次：9[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://119.78.100.204/handle/2XEOYT63/19577
专题	中国科学院计算技术研究所期刊论文_英文
通讯作者	Mollah, Md Nurul Haque
作者单位	1.Univ Rajshahi, Dept Stat, Bioinformat Lab, Rajshahi 6205, Bangladesh 2.Univ Southern Queensland, Fac Business Educ Law & Arts, Sch Commerce, Toowoomba, Qld 4350, Australia 3.Chinese Acad Sci, Ctr High Performance Comp, Joint Engn Res Ctr Hlth Big Data Intelligent Anal, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China 4.Adana AlparslanTurkes Sci & Technol Univ, Fac Engn, Dept Bioengn, TR-01250 Adana, Turkey 5.Univ Sydney, Fac Med & Hlth, NHMRC Clin Trials Ctr, Camperdown, NSW 2006, Australia
推荐引用方式 GB/T 7714	Mosharaf, Md Parvez,Reza, Md Selim,Gov, Esra,et al. Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis[J]. VACCINES,2022,10(5):20.
APA	Mosharaf, Md Parvez,Reza, Md Selim,Gov, Esra,Mahumud, Rashidul Alam,&Mollah, Md Nurul Haque.(2022).Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis.VACCINES,10(5),20.
MLA	Mosharaf, Md Parvez,et al."Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis".VACCINES 10.5(2022):20.